Compounded GLP-1 injections recalled nationwide as sterility of 22 lots cannot be guaranteed
North Carolina's Apothecary Pharma has pulled 22 lots of compounded tirzepatide shots from circulation — here's how to check whether your vials are affected and what to do next.
A North Carolina compounding pharmacy has recalled 23 lots of injectable drugs distributed across the United States because their sterility cannot be assured — including 22 lots of compounded tirzepatide, the active ingredient in the blockbuster weight-loss drugs Mounjaro and Zepbound, and one lot of NAD+ injection.
Apothecary Pharma LLC, based in Cary, North Carolina, initiated the voluntary recall on September 24 and notified recipients by letter. On October 8, the FDA assigned it a Class II classification, which applies when products may produce temporary or medically reversible health problems but are unlikely to cause serious harm. The agency has received no reports of illness or injury tied to the affected products.
The tirzepatide subject to the recall is a prescription injection at a concentration of 18 mg/mL, supplied in a 4 mL multidose vial bearing NDC 85091-001-18. Lot numbers AP-202622 through AP-202625 and AP-202627 through AP-202644 are included, with beyond-use dates that fall between October 7 and November 26, 2026. As for the NAD+ injection, it is a 200 mg/mL prescription product dispensed in a 6 mL multidose vial (NDC 85091-011-06), covering lot AP-202647, which carries a beyond-use date of October 13, 2026.
Anyone who has purchased these products should stop using them immediately and contact their pharmacist or prescriber for guidance. The FDA recommends that patients who experience fever, redness, swelling, or worsening pain at an injection site after receiving one of the affected products seek medical care promptly.
The recall is the latest pressure point for the booming market in compounded GLP-1 alternatives. Apothecary Pharma was among thousands of pharmacies permitted to produce cheaper, non-FDA-approved versions of tirzepatide during a nationwide drug shortage that began in 2022. A study in the Journal of the American Medical Association found that the shortage, which ended in 2025, was supposed to bring compounded production to a halt, yet many producers kept going — frequently by incorporating extra ingredients as a means of circumventing the ban, the Boston Globe reported.
The recall follows a warning letter the FDA sent to Apothecary Pharma — in March, according to the Boston Globe, or December, according to Fox Business and LiveNow Fox — citing serious deficiencies in the company's sterile drug manufacturing practices. According to the FDA, those deficiencies created risks for patients, although the agency has stopped short of drawing a direct link between those findings and the current recall.
Compounded medications are not FDA-approved. Unlike brand-name drugs, they do not undergo FDA review for safety, effectiveness, or quality before being marketed. The FDA-approved brand-name versions of tirzepatide — Mounjaro and Zepbound, made by Eli Lilly — are not affected by this recall.
The recall lands as federal regulators have intensified scrutiny of the compounded GLP-1 market. This month the FDA formally warned patients not to use compounded GLP-1s unless their individual medical needs cannot be met by brand-name drugs, citing reports of improper storage during shipping, dosing errors leading to adverse reactions and hospitalizations, and products made with unapproved ingredients, according to the Boston Globe. The agency has also issued warning letters against small pharmacies for marketing their compounded products as equivalent to brand-name labels.
Despite the regulatory pressure, demand for compounded alternatives remains substantial. In 2024, roughly one in three GLP-1 patients used compounded versions; that figure has since fallen to around one in five, according to a July Gallup report cited by the Boston Globe, as overall GLP-1 use has continued to grow.
The recall remains ongoing. Officials from the FDA and Apothecary Pharma did not respond to a request for comment from the Boston Globe.
Why it matters — Anyone using compounded tirzepatide injections from Apothecary Pharma should check their vial lot numbers now — and the recall is a signal of broader regulatory risk for the millions of Americans relying on cheaper compounded GLP-1 alternatives.
⚠ Not yet confirmed
- The FDA warning letter to Apothecary Pharma was sent in December (2025).
- Changed '23 vials' to '23 lots' in opening paragraph for accuracy (sources describe lots, not individual vials)
Sources differ on Date of FDA warning letter to Apothecary Pharma: March 2026 (bostonglobe.com) vs December 2025 (foxbusiness.com) vs December 2025 (livenowfox.com)
Reported by usatoday.com, foxbusiness.com, bostonglobe.com, independent.co.uk, livenowfox.com
- Eli LillyAmerican pharmacist, Union Army officer, businessman, philanthropist